TABLE 3.
Reasons for concomitant medication use for the 44 COVID‐19 patients in the experimental group and the control group
| Experimental group (N = 26) | Control group (N = 18) | ||||||
|---|---|---|---|---|---|---|---|
| Category | Severe (N = 16) | Critically ill (N = 10) | P a | Severe (N = 10) | Critically ill (N = 8) | P b | P c |
| Symptomatic treatment, n (%) | 14 (87.50) | 10 (100.00) | .508 | 10 (100.00) | 8 (100.00) | N/A | .505 |
| Antiviral therapy, n (%) | 15 (93.75) | 8 (80.00) | .538 | 10 (100.00) | 8 (100.00) | N/A | .258 |
| Antibacterial treatment, n (%) | 9 (56.25) | 6 (60.00) | 1.000 | 8 (80.00) | 6 (75.00) | 1.000 | .167 |
| Hormone, n (%) | 7 (43.75) | 7 (70.00) | .248 | 7 (70.00) | 7 (87.50) | .588 | .105 |
| Gut microflora modulator, n (%) | 1 (6.25) | 0 (0.00) | 1.000 | 3 (30.00) | 1 (12.50) | .588 | .142 |
| Extracorporeal blood purification system, n (%) | 1 (6.25) | 9 (90.00) | <.001* | 2 (20.00) | 7 (87.50) | .015* | .447 |
| Traditional Chinese medicine treatment, n (%) | 9 (56.25) | 6 (60.00) | 1.000 | 6 (60.00) | 7 (87.50) | .314 | .325 |
| Basic disease medication, n (%) | 2 (12.50) | 3 (30.00) | .340 | 2 (20.00) | 5 (62.50) | .145 | .183 |
Note.
*
Represents significant difference (P < .05); P a value is the experimental group of the difference between severe and critically ill patients in each type of combination medication in the experimental group; P b is the difference test between severe and critically ill patients in each type of combination medication in the control group; P c is the test group in each type of combination medication test the difference with the control group (do not distinguish the severity of the disease); “n” represents number; “N/A” represents not applicable.